Stock Research for ARQL

ARQL

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ARQL Stock Chart & Research Data

The ARQL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARQL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARQL Due diligence Resources & Stock Charts

The ARQL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARQL Detailed Price Forecast - CNN Money CNN View ARQL Detailed Summary - Google Finance
Yahoo View ARQL Detailed Summary - Yahoo! Finance Zacks View ARQL Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ARQL Trends & Analysis - Trade-Ideas Barrons View ARQL Major Holders - Barrons
NASDAQ View ARQL Call Transcripts - NASDAQ Seeking View ARQL Breaking News & Analysis - Seeking Alpha
Spotlight View ARQL Annual Report - CompanySpotlight.com OTC Report View ARQL OTC Short Report - OTCShortReport.com
TradeKing View ARQL Fundamentals - TradeKing Charts View ARQL SEC Filings - Bar Chart
WSJ View Historical Prices for ARQL - The WSJ Morningstar View Performance/Total Return for ARQL - Morningstar
MarketWatch View the Analyst Estimates for ARQL - MarketWatch CNBC View the Earnings History for ARQL - CNBC
StockMarketWatch View the ARQL Earnings - StockMarketWatch MacroAxis View ARQL Buy or Sell Recommendations - MacroAxis
Bullish View the ARQL Bullish Patterns - American Bulls Short Pains View ARQL Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ARQL Stock Mentions - StockTwits PennyStocks View ARQL Stock Mentions - PennyStockTweets
Twitter View ARQL Stock Mentions - Twitter Invest Hub View ARQL Investment Forum News - Investor Hub
Yahoo View ARQL Stock Mentions - Yahoo! Message Board Seeking Alpha View ARQL Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ARQL - SECform4.com Insider Cow View Insider Transactions for ARQL - Insider Cow
CNBC View ARQL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARQL - OTC Markets
Yahoo View Insider Transactions for ARQL - Yahoo! Finance NASDAQ View Institutional Holdings for ARQL - NASDAQ


Stock Charts

FinViz View ARQL Stock Insight & Charts - FinViz.com StockCharts View ARQL Investment Charts - StockCharts.com
BarChart View ARQL Stock Overview & Charts - BarChart Trading View View ARQL User Generated Charts - Trading View




Latest Financial News for ARQL


ArQule, Inc. (ARQL): Are Hedge Funds Right About This Stock?
Posted on Tuesday December 11, 2018

Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th. Forty percent of the S&P 500 constituents were down more than 10%. The average return of a randomly picked stock […]


ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting
Posted on Monday December 03, 2018

ArQule, Inc. (ARQL) yesterday presented preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego.


The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
Posted on Sunday December 02, 2018

Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...


ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies
Posted on Thursday November 29, 2018

ArQule, Inc. (ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company’s Phase 1 dose escalation study in patients with relapsed or refractory hematologic malignancies (ARQ 531-101) that are being presented in a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition on December 3, 2018 in San Diego. The C481S-mutation is a known resistance mechanism for first generation irreversible BTK inhibitors.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.